Comparing ME/CFS following mononucleosis with Long COVID.
Jason, Leonard A, Furst, Jacob, Katz, Ben Z · Chronic illness · 2026 · DOI
Quick Summary
Researchers compared people who developed ME/CFS after infectious mononucleosis with people who developed Long COVID after SARS-CoV-2 infection, looking at their symptoms, coping strategies, and mood. They observed that the Long COVID group reported fewer symptoms overall than those with severe ME/CFS, but more symptoms than those with moderate ME/CFS. These are early findings from one study, and it remains unclear how well insights from Long COVID apply to ME/CFS specifically.
Why It Matters
This study provides preliminary data on how post-infectious illnesses following different pathogens may present along a clinical spectrum. By analogy, understanding symptom patterns in Long COVID may help clinicians recognize and stratify severity in ME/CFS following other triggers; however, the relevance of Long COVID findings to ME/CFS aetiology and pathophysiology remains unclear.
Observed Findings
Long COVID participants were observed to report an intermediate symptom burden, lower than the severe ME/CFS group but higher than the moderate ME/CFS group.
Somatic symptoms, coping strategies, depression, anxiety, and functional status were compared across ME/CFS (moderate and severe) and Long COVID groups.
The study cohort included college students prospectively enrolled before IM onset and a matched SARS-CoV-2–infected sample.
Inferred Conclusions
The authors interpret the symptom-burden gradient (moderate ME/CFS < Long COVID < severe ME/CFS) as consistent with a spectrum of post-infectious illness presentation.
They suggest these comparative data may help elucidate pathophysiological mechanisms in post-viral conditions, though they do not specify which mechanisms.
Remaining Questions
Do symptom-burden differences reflect distinct underlying pathophysiologies, or do they reflect differences in case ascertainment and cohort selection?
How stable are these phenotypic distinctions over time, and do they predict treatment response differently?
Which specific behavioral, immunological, or metabolic factors account for the observed gradation in symptom burden?
Do findings from this college-student cohort generalise to older or more clinically severe populations with ME/CFS or Long COVID?
What This Study Does Not Prove
This study does not establish causation or mechanistic links between infectious exposure and illness severity. It does not confirm whether symptom differences reflect different pathophysiologies or different case ascertainment practices. It does not validate the moderate/severe ME/CFS criteria used, nor does it establish that Long COVID and ME/CFS are fundamentally comparable post-infectious syndromes.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.